Replies to post #32189 on Ariad Pharmaceuticals Inc fka ARIA

[iandy]

I don't pretend to be an expert on the science but it occured to me Bafetinib might have a shot at PD. The study was funded by the Michael J. Fox Foundation, Parkinson’s Disease Foundation, San Antonio Area Foundation, American Parkinson Disease Association and Executive Research Council of UTHSCSA. I figure they had their choice of inhibitors and chose Bafetinib because it was designed to be a superior BCR-ABL/Lyn dual tyrosine kinase inhibitor.

Of course this whole subject of the possible application of this class of drugs to neurodegenerative diseases is a long shot.
Elan's bapineuzumab was wildly effective in mice. Shane Willmot had them doing amazing things:

http://action.scholastic.com/issues/09_05_11/Videos

The drug proved to be a bust in humans.

[bellweather1]

I hope my main point was clear

It certainly was!

Great post regarding the relative BBB penetration of TKIs-

Answers the question I posited to Biomaven yesterday-

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89888698

However, I'd like to see some of your sourcing, particularly the ones regarding the Pona data.

Certainly seems like it could be a game changer, and I have to believe that Ariad has been considering this potential for quit some time.

In fact, I wouldn't be too surprised to hear an announcement relating to it(or some other Pona application)ahead of the long awaited(by some)next compound.

In addition, if the potential is as great as it seems to be, I would also expect to see some form of IST materialize in the near future, particularly if Ariad hesitates(which would be a shame because early mover advantage, regardless of the absolute efficacy of the drug, is, as we've seen in cml, very valuable).

Nevertheless, I suspect that with all they have going on, the prospect of starting trials within a completely different tx and pt context, (particularly if they adhere to they're pure "go-it-alone" mantra), would be somewhat daunting at this point.

Therefore, since this is an entirely different application type, they may, in the interest of expediency, be open to some form of collaboration.

Either way, it will be interesting to see. But if, as you say, they have clear superiority regarding CNS penetration, and there's not some yet to be discovered/revealed co-occurring mechanisms(that Pona lacks)that are essential to this type of application,

then it would appear Harvey is sitting with yet another enormous ball in his court...

Best regards(and thanks again for the research),

bw